|Echo Therapeutics, Inc.|
99 Wood Avenue South
United States - Map
Echo Therapeutics, Inc. is engaged in the development of transdermal skin permeation and diagnostic medical devices. It is developing Symphony CGM system (Symphony), a needle-free wireless continuous glucose monitoring system for use in hospital critical care units; and Symphony SkinPrep system, a component of its Symphony for enhanced skin permeation that enables extraction of analytes, such as glucose. The company is also engaged in the development Durhalieve, an AzoneTS formulation of triamcinolone acetonide that has completed Phase III clinical trials for the treatment of corticosteroid-responsive dermatoses. It has a licensing agreement with Ferndale Pharma Group, Inc. to develop, market, sell, and distribute Prelude SkinPrep system for skin preparation prior to the application of topical anesthetics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community; a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell Symphony for continuous glucose monitoring for use by medical facilities and/or individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd. The company was founded in 1989 and is headquartered in Iselin, New Jersey.
|Mr. Scott W. Hollander ,
Chief Exec. Officer, Pres and Director
|Mr. Charles T. Bernhardt CPA, M.B.A.,
Interim Chief Financial Officer
|Mr. Alan W. Schoenbart CPA,
Chief Financial Officer
|Mr. Thomas H. Bishop ,
VP of Operations and Product Devel.
|Ms. Christine H. Olimpio ,
Director of Investor Relations & Corp. Communications
|Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|